T Cell Antigen Coupler Platform Generating Patient-Derived Cell Therapies to Target Solid Tumors with Dr. Paul Lammers Triumvira Immunologics TRANSCRIPT
Download PDFMar 13, 2023
Dr. Paul Lammers, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells. At the forefront of the next generation of immune-oncology,...
Mar 13, 2023
Dr. Paul Lammers, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells. At the forefront of the next generation of immune-oncology,...
Converting Liver Tumors into Low-Oxygen Environment to Activate Drug to Drive Cell Death with Dr. Ray Lee Teclison TRANSCRIPT
Download PDFNov 14, 2022
Dr. Ray Lee is the CEO of Teclison, focused on overcoming the limitations of existing immunotherapy for treating liver cancer in part caused by the fact that the liver is a highly immunotolerant organ. The key is to make the tumor a low-oxygen environment and delivering a drug that only works on the tumor.
Ray...
Nov 14, 2022
Dr. Ray Lee is the CEO of Teclison, focused on overcoming the limitations of existing immunotherapy for treating liver cancer in part caused by the fact that the liver is a highly immunotolerant organ. The key is to make the tumor a low-oxygen environment and delivering a drug that only works on the tumor.
Ray...
Using Oncolytic Viral Immunotherapy to Kill Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics TRANSCRIPT
Download PDFSep 19, 2022
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of...